Subjects undergoing colonoscopy
Conditions
Interventions
Control group:Polyethylene glycol + Simethicone
Trial group:Concentrated solution of magnesium, sodium and potassium sulfate for oral use
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Between the ages of 18 and 65; 2. There are indications for colonoscopy; 3. Have a clear sense of awareness and the ability to act independently, and can cooperate with the implementation of the intervention. 4. Agree to participate in this study.
Exclusion criteria
Exclusion criteria: 1.Patients with known or suspected intestinal obstruction or stenosis, active inflammatory bowel disease (e.g. Crohn's disease and ulcerative colitis), known or suspected gastrointestinal perforation, toxic colitis, toxic megacolon, gastric emptying disorders (e.g., gastric weakness, gastric retention); 2.Acute abdominal disease requiring surgery (e.g. acute appendicitis), nausea and vomiting, ascites, history of abdominal surgery (e.g. colostomy, colectomy, gastric bypass, gastric anastomosis); 3.Significant electrolyte disturbances (e.g., hypernatremia, hyponatremia, hyperphosphatremia, hypokalemia, hypocalcemia), dehydration, or electrolyte abnormalities secondary to the use of diuretics or other medications; 4.Severe renal insufficiency (glomerular filtration rate < 30 ml/min/1.73 m^2), hepatic insufficiency or cardiac insufficiency (including heart failure); 5.Impairment of consciousness; 6. Patients who are pregnant, breastfeeding, or who refuse (if they have fertility potential) a pregnancy test. 7. Patients allergic to the ingredients of the preparation (polyethylene glycol, sodium sulfate, potassium sulfate, magnesium sulfate); 8. Patients who are unable to follow the study procedures. 9. Patients who participated in an investigational surgical drug or device study in the past 30 days. 10. Patients who withdraw their consent after completing the baseline procedure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety evaluation;Tolerance evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Effectiveness evaluation; | — |
Countries
China
Contacts
Public ContactNian Bixiao
Peking University First Hospital
Outcome results
None listed